University Multiprofile Hospital For Active Treatment St. Ivan Rilski EAD
- Address
- lock Available on a paid plan
University Multiprofile Hospital For Active Treatment St. Ivan Rilski EAD
The University Multiprofile Hospital For Active Treatment St. Ivan Rilski EAD serves as a leading clinical research institution with extensive expertise in autoimmune disorders, oncology, and neurological diseases. The center demonstrates particular strength in conducting advanced Phase 3 trials and comparative effectiveness studies, evaluating both novel therapeutic agents and biosimilar candidates across multiple therapeutic areas.
- Multiple Sclerosis and neurological disorders, including relapsing-remitting MS, progressive MS, and innovative BTK inhibitor therapies
- Autoimmune and inflammatory conditions, including systemic lupus erythematosus, rheumatoid arthritis, and axial spondyloarthritis
- Hematologic malignancies and oncology, specializing in chronic lymphocytic leukemia, multiple myeloma, and lymphomas with immunoglobulin therapy research
- Solid tumor malignancies, including hormone receptor-positive breast cancer, prostate cancer, and renal cell carcinoma
The hospital's research portfolio reflects a commitment to evaluating targeted immunotherapies, JAK inhibitors, and monoclonal antibodies in complex disease states. With capabilities spanning from pharmacokinetic comparability studies to long-term safety extension trials, the center contributes valuable data on both biosimilar development and breakthrough therapies. The institution's participation in multi-center international trials demonstrates its capacity to deliver high-quality clinical research data across diverse patient populations with coexisting medical conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 81 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 70 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Bayer AG5trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Multiprofile Hospital For Active Treatment St. Ivan Rilski EAD
lock Showing 1 of 39 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 81 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Gadoteric Acid | 3 | Unknown | 2023-09-20 | 2023-10-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.